| Index | — | P/E | — | EPS (ttm) | -1.90 | Insider Own | 2.54% | Shs Outstand | 96.84M | Perf Week | 6.16% |
| Market Cap | 3.64B | Forward P/E | — | EPS next Y | -4.67 | Insider Trans | 1.03% | Shs Float | 90.90M | Perf Month | 1.76% |
| Enterprise Value | 2.72B | PEG | — | EPS next Q | — | Short Float | 8.08% | Perf Quarter | -40.54% | ||
| Income | -346.00M | P/S | — | EPS this Y | — | Short Ratio | 5.15 | Perf Half Y | -33.75% | ||
| Sales | 8.00M | P/B | 2.93 | EPS next Y | — | ROA | -31.58% | Short Interest | 7.35M | Perf YTD | -14.70% |
| Book/sh | 12.83 | P/C | 3.91 | EPS next 5Y | — | ROE | -43.98% | 52W High | 72.66 -47.39% | Perf Year | -8.80% |
| Cash/sh | 9.61 | P/FCF | — | EPS past 3/5Y | — | ROIC | -35.10% | 52W Low | 33.38 14.53% | Perf 3Y | 23.84% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | -3.85% -24.21% | Gross Margin | 0.00% | Volatility | 3.39% 3.34% | Perf 5Y | 25.06% |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 1.46 | Perf 10Y | 349.76% |
| Dividend Ex-Date | — | Quick Ratio | 21.02 | Sales Y/Y TTM | -100.00% | Profit Margin | 0.00% | RSI (14) | 48.43 | Recom | 2.05 |
| Dividend Gr. 3/5Y | — | Current Ratio | 21.02 | EPS Q/Q | -3.74% | SMA20 | 6.34% | Beta | 0.08 | Target Price | 68.63 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | — | SMA50 | -13.97% | Rel Volume | 0.80 | Prev Close | 37.62 |
| Employees | 364 | LT Debt/Eq | 0.00 | Earnings | Nov 09 | SMA200 | -26.96% | Avg Volume | 1.56M | Price | 38.23 |
| IPO Date | Nov 05, 2014 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 2.76% — | Net Debt/EBITDA | — | Volume | 1,246,527 | Change | 1.62% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-28-26 | Reiterated | Jefferies | Buy | $100 → $90 |
| Sep-18-26 | Reiterated | Robert W. Baird | $97 → $90 | |
| Sep-18-26 | Downgrade | Deutsche Bank | Buy → Hold | $90 → $46 |
| Sep-18-26 | Reiterated | Wells Fargo | Overweight | $69 → $64 |
| Sep-18-26 | Reiterated | Wedbush | Outperform | $42 → $55 |
| Sep-18-26 | Reiterated | RBC Capital | Outperform | $81 → $70 |
| Sep-18-26 | Reiterated | Needham | Buy | $78 → $60 |
| Aug-10-26 | Reiterated | H.C. Wainwright | Buy | $53 → $74 |
| Aug-07-26 | Reiterated | RBC Capital | Outperform | $80 → $81 |
| May-10-26 | Reiterated | Wells Fargo | Overweight | $68 → $69 |
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | FY 2017 12/31/2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 8 | 0 | 0 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 3 | 3 | 168 | — | — | — | — | — | — | |
| Gross Profit | 5 | -3 | -168 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 80 | 69 | 47 | — | — | — | — | — | — | |
| Research and Development | 301 | 210 | 168 | — | — | — | — | — | — | |
| Other Operating Expense | -3 | -2 | -168 | — | — | — | — | — | — | |
| Operating Income | -373 | -279 | -214 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 28 | 41 | 31 | — | — | — | — | — | — | |
| Net Income Before Taxes | -345 | -238 | -183 | — | — | — | — | — | — | |
| Income Taxes | 1 | -4 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -346 | -234 | -182 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -346 | -234 | -182 | — | — | — | — | — | — | |
| Net Income | -346 | -234 | -182 | — | — | — | — | — | — | |
| EPS (Recurring) | -4.36 | -3.01 | -2.73 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -4.36 | -3.01 | -2.73 | — | — | — | — | — | — | |
| EPS (Diluted) | -4.36 | -3.01 | -2.73 | — | — | — | — | — | — | |
| EBITDA | -342 | -236 | -211 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 442.60 | — | — | — | — | — | — | — | — | |
| Gross Margin | 62.50 | — | — | — | — | — | — | — | — | |
| Operating Margin | -4,662.50 | — | — | — | — | — | — | — | — | |
| Net Margin | -4,325.00 | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 79 | 78 | 67 | — | — | — | — | — | — | |
| Market Capitalization | 3,541 | 3,058 | 3,086 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Kelly Thomas Patrick | Chief Financial Officer | Oct 15 '26 | Option Exercise | 0.00 | 7,500 | 0 | 22,500 | Oct 16 |
| MORTIMER IAN | PRESIDENT & CEO | Sep 30 '26 | Buy | 37.38 | 30,000 | 1,121,400 | 49,923 | Oct 01 |
| Kelly Thomas Patrick | Chief Financial Officer | Sep 30 '26 | Buy | 37.32 | 15,000 | 559,740 | 15,000 | Oct 01 |
| Svoronos Dawn | Director | Sep 01 '26 | Option Exercise | 8.15 | 5,144 | 41,924 | 31,373 | Sep 03 |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | Aug 28 '26 | Sale | 60.25 | 7,068 | 425,829 | 2 | Aug 31 |
| GANNON STEVEN | Director | Aug 11 '26 | Sale | 64.06 | 10,000 | 640,550 | 1,870 | Aug 13 |
| Cannon Gillian | Director | Jun 05 '26 | Sale | 53.14 | 1,190 | 63,237 | 1,455 | Jun 08 |
| PATOU GARY | Director | Jun 05 '26 | Sale | 53.14 | 1,322 | 70,251 | 24,896 | Jun 08 |
| Cannon Gillian | Director | Jun 01 '26 | Option Exercise | 0.00 | 2,645 | 0 | 2,645 | Jun 03 |
| PATOU GARY | Director | Jun 01 '26 | Option Exercise | 0.00 | 2,645 | 0 | 26,218 | Jun 03 |
| Machado Patrick | Director | Jun 01 '26 | Option Exercise | 0.00 | 2,645 | 0 | 2,645 | Jun 03 |
| Gover Justin D. | Director | Jun 01 '26 | Option Exercise | 0.00 | 2,645 | 0 | 2,645 | Jun 03 |
| GAROFALO ELIZABETH A. | Director | Jun 01 '26 | Option Exercise | 0.00 | 2,645 | 0 | 2,645 | Jun 03 |
| GANNON STEVEN | Director | Jun 01 '26 | Option Exercise | 0.00 | 2,645 | 0 | 13,286 | Jun 03 |
| Svoronos Dawn | Director | Jun 01 '26 | Option Exercise | 0.00 | 2,645 | 0 | 27,645 | Jun 03 |